Project Grant R44HL180159
Award Date 9/1/26
Completion Date 7/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60616, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Icardio.ai Corporation $290,142 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, for an artificial intelligence-enabled diagnostic support system for echocardiography. Performance of the award concludes on August 31, 2027, at the recipient's location in Century City, California. The project addresses the shortage of trained echocardiographers and the infrastructure constraints that limit adoption of...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart Lung and Blood Institute awarded Case Western Reserve University $1,573,126 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence-based decision-support tool that identifies patients at risk of myocardial ischemia using low-cost or no-cost screening data. The tool will analyze CT calcium scores, electrocardiogram data, and clinical risk factors to serve as a gatekeeper strategy for determining which patients...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart Lung and Blood Institute awarded Precisionbio AI, LLC $374,472 on September 1, 2026, to develop a machine learning-driven precision dosing system for warfarin anticoagulation therapy under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will develop and validate a predictive platform that integrates lifestyle, clinical, and pharmacogenomic data through a multi-model ensemble combining interpretable machine learning models with deep neural networks and...
- The National Heart, Lung, and Blood Institute awarded Nightingale Labs Corp $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to commercialize non-contact cardiopulmonary monitoring technology for heart failure management. Nightingale Labs is developing a fully automated, non-contact home bed sensor platform that monitors cardiopulmonary physiology without requiring active patient participation, aimed at detecting clinical deterioration in heart...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop individualized prediction methods for heart failure progression using digital twins and explainable reinforcement learning. The project will characterize cardiac performance at the individual level using primary echocardiographic images, quantitative echocardiographic measures, and arterial pulse wave velocity...
- RCE Technologies, Inc. was awarded a $255,892 Small Business Innovation Research Phase I Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program to develop a proof-of-concept machine learning-based diagnostic system for detecting myocardial infarction and ischemia in real-time. The system aims to provide point-of-care clinical classification for heart attack cases using a novel, portable device integrating the awardee's proprietary external...